Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
116 studies found for:    Open Studies | "Neuroblastoma"
Show Display Options
Rank Status Study
21 Recruiting Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
Condition: Neuroblastoma
Intervention: Radiation: External beam radiotherapy
22 Recruiting Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma
Condition: Relapsed or Refractory Neuroblastoma
Intervention: Biological: GD2-targeted CAR-T cells
23 Recruiting Trial of Tolcapone With Oxaliplatin for Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Tolcapone;   Drug: Oxaliplatin
24 Recruiting High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Carboplatin;   Biological: Autologous stem cell infusion;   Biological: Granulocyte colony stimulating factor;   Radiation: Radiation therapy;   Drug: Isotretinoin (13-cis-retinoic acid);   Drug: Melphalan;   Drug: Etoposide
25 Recruiting European Low and Intermediate Risk Neuroblastoma Protocol
Condition: LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES
Intervention: Drug: chemotherapy
26 Recruiting Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Condition: Neuroblastoma
Interventions: Drug: bortezomib;   Drug: crizotinib;   Drug: dasatinib;   Drug: lapatinib;   Drug: sorafenib;   Drug: vorinostat;   Drug: DFMO
27 Recruiting Impact of Image-defined Risk Factors on the Outcome of Patients With Neuroblastoma: A Retrospective Study
Condition: Neuroblastoma
Intervention:
28 Recruiting Post-Marketing Assessment of Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients
Condition: Neuroblastoma
Intervention: Drug: Dinutuximab
29 Recruiting Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors
Condition: Neuroblastoma
Intervention: Biological: Humanized 3F8 Monoclonal Antibody (Hu3F8)
30 Recruiting Parental Decision-Making for Children With Relapsed Neuroblastoma
Condition: Relapsed Neuroblastoma
Intervention:
31 Recruiting Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
Condition: Neuroblastoma
Interventions: Drug: Bevacizumab;   Drug: Temozolomide;   Drug: Irinotecan;   Drug: Topotecan
32 Recruiting Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients
Condition: Neuroblastoma
Interventions: Device: propofol;   Drug: ropivacaine;   Behavioral: Wong-Baker FACES® Pain Rating Scale;   Behavioral: Post-procedural quality of life (QOL)
33 Recruiting A Study of High Risk Induction Chemotherapy for Neuroblastoma Without Prophylactic Administration of Myeloid Growth Factors
Condition: Neuroblastoma
Interventions: Drug: Topotecan;   Drug: Cyclophosphamide;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Sargramostim
34 Recruiting Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification
Condition: Neuroblastoma
Intervention: Procedure: Blood sampling
35 Not yet recruiting Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Nivolumab;   Drug: Ch14.18/CHO
36 Recruiting Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma
Condition: Neuroblastoma
Intervention: Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
37 Recruiting Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Condition: Neuroblastoma
Intervention: Biological: Hu3F8 With GM-CSF
38 Recruiting Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma
Condition: Neuroblastoma Recurrent
Interventions: Drug: Dasatinib;   Drug: Rapamycin;   Drug: Irinotecan;   Drug: Temozolomide
39 Recruiting Response-based Treatment of High-risk Neuroblastoma
Condition: Newly Diagnosed High Risk Neuroblastoma
Interventions: Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Carboplatin;   Procedure: Tandem HDCT/auto-SCT;   Radiation: Radiotherapy;   Drug: Interleukin-2;   Drug: Isotretinoin;   Radiation: MIBG
40 Recruiting Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
Condition: Neuroblastoma Recurrent
Interventions: Drug: DFMO;   Drug: Bortezomib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.